Results 131 to 140 of about 50,209 (254)

Molecular Regulation of Bone Turnover in Juvenile Idiopathic Arthritis: Animal Models, Cellular Features and TNFα

Frontiers in Bioscience-Landmark
We review the abnormal bone turnover that is the basis of idiopathic inflammatory or rheumatoid arthritis and bone loss, with emphasis on Tumor Necrosis Factor-alpha (TNFα)-related mechanisms.
Harry C Blair, Jonathan Soboloff, Irina L Tourkova, Jamie L. McCall, Suravi Ray, Margalit E Rosenkranz, Cristina Sobacchi, Lisa J Robinson, John B Barnett   +8 more
doaj   +1 more source

Is juvenile rheumatoid arthritis/juvenile idiopathic arthritis different from rheumatoid arthritis?

, 2002
CHAPTER SUMMARY: The chronic arthropathies of childhood share clinical and pathological features with rheumatoid arthritis (RA) in adults. Both are autoimmune diseases characterized by a destructive arthropathy. Both are likely to be complex genetic traits, with autoantibodies and with a type-1-T-helper-cell cytokine profile in disease tissues.
Prahalad, Sampath, Glass, David N
openaire   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.
The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld, Geetha S. Iyer, Suna C. Seo, Andrew Giffin, Andrew L. Simon, Sheryl A. Kluberg, Emma R. Hoffman, Jamal T. Jones, Sarah K. Dutcher, Joyce A. Korvick   +9 more
wiley   +1 more source

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study

Muscle &Nerve, Volume 73, Issue 6, Page 1044-1057, June 2026.
ABSTRACT Introduction/Aims Comorbidities are frequent in myasthenia gravis (MG) and may affect treatment choices. Conversely, MG treatments may impact the risk of comorbidity. Our objective was to examine comorbidity and MG treatment patterns in nationwide MG cohorts in Denmark, Finland, and Sweden. Methods We included individuals with ≥ 2 MG diagnoses
Sari Atula, Fredrik Piehl, Ingrid Schager, Fredrik Berggren, Karin Humle, Mari Savolainen, Didier Pitsi, Juha Mehtälä, Aino Vesikansa, Riina‐Minna Väänänen, Tero Ylisaukko‐oja, John Vissing   +11 more
wiley   +1 more source

Age‐Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT While the efficacy of canakinumab, an anti‐interleukin‐1β monoclonal antibody, is well‐established, its safety profile, particularly across different age groups, remains inadequately explored. Using the FDA Adverse Event Reporting System (FAERS) database, this study evaluated postmarketing safety by analyzing adverse event (AE) reports from ...
Youyang Wang, Ngasin Lam, Xiaoming Huang, Yang Jiao   +3 more
wiley   +1 more source

Diffusion‐Weighted Imaging for the Evaluation of the Sacroiliac Joint in Pediatric Patients

Arthritis Care &Research, Volume 78, Issue 5, Page 630-638, May 2026.
Objective Maturational signal in the sacroiliac joint (SIJ) of skeletally immature youth is often misinterpreted as inflammation. Diagnostic tools that improve specificity are greatly needed. Apparent diffusion coefficient (ADC) values from diffusion‐weighted imaging (DWI), when used with standard imaging, may enhance diagnostic accuracy.
Michael L. Francavilla, Timothy G. Brandon, Dmitry Khrichenko, Rui Xiao, Nancy A. Chauvin, Asef Khwaja, Pamela F. Weiss   +6 more
wiley   +1 more source

Accuracy of Diagnostic Codes and Algorithms Used to Identify Rheumatoid Arthritis and Juvenile Idiopathic Arthritis in Administrative Claims and Electronic Health Records: Systematic Review and Meta‐Analysis

Arthritis Care &Research, Volume 78, Issue 5, Page 670-682, May 2026.
Objective This systematic review aimed to assess the diagnostic accuracy of algorithms used to identify rheumatoid arthritis and juvenile idiopathic arthritis in electronic health records. Methods We searched Medline, Embase, and Cochrane Central Register for Controlled Trials databases and included studies that validated case definitions against a ...
Constanza Saka‐Herrán, Jessica Bennett, Yara Alkabti, Muhammad Fatir, Barbara Clyne, Caroline McCarthy, Gráinne Tynan, Nikki Dunne, Michelle Flood, Eoghan McCarthy, Frank Moriarty   +10 more
wiley   +1 more source

Quantitative Muscle Magnetic Resonance Imaging Demonstrates Resolution of Muscle Edema in Refractory Dermatomyositis: A Post Hoc Analysis of a Proof‐of‐Concept Clinical Trial of Tofacitinib

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective To evaluate changes in muscle edema using short‐tau inversion recovery (STIR) imaging and quantitative diffusion‐weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping in patients with refractory dermatomyositis (DM) treated with tofacitinib. Methods This post hoc imaging analysis included patients from a 12‐week, open‐label
Mona Dabiri, Anshula Nallapati, Marwin Groener, Patrick Debs, Jemima Albayda, Eleni Tiniakou, Lisa Christopher‐Stine, Laura Fayad, Julie J. Paik   +8 more
wiley   +1 more source

Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry

ACR Open Rheumatology, Volume 8, Issue 5, May 2026.
Objective Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) such as semaglutide (SEM) and tirzepatide (TZP) were initially approved for type 2 diabetes management but are increasingly used for weight loss. Limited data exist on real‐world use among patients with rheumatic and musculoskeletal diseases (RMDs).
Nicholas P. McCormick, Cristiano S. Moura, Jingyi Zhang, Emily E. Holladay, Fenglong Xie, Tapan Mehta, Joshua F. Baker, Jeffrey R. Curtis   +7 more
wiley   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source